<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229602</url>
  </required_header>
  <id_info>
    <org_study_id>FY-CP-06-201909-01</org_study_id>
    <nct_id>NCT04229602</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers</brief_title>
  <official_title>Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules and EFEXOR® XR Under Fed Conditions in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the human bioequivalence of two Venlafaxine&#xD;
      Hydrochloride Sustained-Release Capsules (75 mg) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the human bioequivalence of Venlafaxine&#xD;
      Hydrochloride Sustained-Release Capsules (75 mg) produced by Beijing Winsunny Pharmaceutical&#xD;
      Co., Ltd and EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer&#xD;
      Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD), as well as the safety of&#xD;
      the tested preparation, and to provide basis for the evaluation of the quality and efficacy&#xD;
      consistency of the tested preparation and the reference preparation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">July 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>Cmax - Maximum Observed Concentration (of Venlafaxine in Plasma)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC0-t</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC0-∞</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>AUC0-∞- Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>Venlafaxine Hydrochloride Sustained-Release Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of Hydrochloride Sustained-Release Capsules 75 mg under Fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: EFEXOR® XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of EFEXOR® XR 75mg under Fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg</intervention_name>
    <description>A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.</description>
    <arm_group_label>Venlafaxine Hydrochloride Sustained-Release Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFEXOR® XR</intervention_name>
    <description>EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)</description>
    <arm_group_label>Active Comparator: EFEXOR® XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects are fully informed and voluntarily consent to participate in this study;&#xD;
&#xD;
          2. Healthy adult volunteers of ≥18 years old and ≤ 65 years old, male or female;&#xD;
&#xD;
          3. Body weight ≥ 50.0 kg for male and 45.0 kg for female;&#xD;
&#xD;
          4. Subjects are able to communicate well with the investigator and to understand and&#xD;
             comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects enroll in other clinical trials and take corresponding experimental drugs&#xD;
             within 90 days before the trial, or participate in other clinical trials;&#xD;
&#xD;
          2. The results of physical examination, vital signs examination, clinical laboratory&#xD;
             examination (blood routine, urine routine, blood biochemistry, coagulation function,&#xD;
             immunity 8 items, blood pregnancy (female only)), 12-lead electrocardiogram (ECG) are&#xD;
             clinical significant;&#xD;
&#xD;
          3. Any previous history and present medical history that may affect the safety of the&#xD;
             trial or the in-vivo process of the drug, especially a history of liver, kidney,&#xD;
             endocrine, cardiovascular, nervous, gastrointestinal, lung, tumor, immune, skin, blood&#xD;
             or metabolic disorders that the investigator considers clinically significant;&#xD;
&#xD;
          4. Any history of surgery or trauma that may affect the safety of the test or the in-vivo&#xD;
             process of the drug;;&#xD;
&#xD;
          5. Subjects have depression, mania and other mental disorders, or have suicidal&#xD;
             tendencies;&#xD;
&#xD;
          6. Subjects have the history of angle-closure glaucoma;&#xD;
&#xD;
          7. Heavy smokers (average daily smoking of more than 5 cigarettes in the 90 days before&#xD;
             the trial), heavy drinkers (average weekly drinking of more than 14 units of alcohol&#xD;
             in the 90 days before the trial, 1 unit =360 mL beer or 45 mL 40% spirits or 150 mL&#xD;
             wine), and subjects who could not promise to quit smoking and drinking during the&#xD;
             experiment;&#xD;
&#xD;
          8. Subjects had taken any alcoholic product within 24 hours before the test, or had&#xD;
             tested positive for alcohol breath test;&#xD;
&#xD;
          9. Allergic to any component of venlafaxine hydrochloride sustained-release capsules, or&#xD;
             with a history of specific allergies (asthma, urticaria, eczema, etc.), or allergic&#xD;
             constitution (such as allergic to two or more drugs or food);&#xD;
&#xD;
         10. Lactose intolerance (a history of diarrhea from drinking milk);&#xD;
&#xD;
         11. Previous history of drug use, drug abuse, or positive urine drug screening;&#xD;
&#xD;
         12. Subjects who have donated blood or lost blood equal to or more than 200 mL within 90&#xD;
             days before the test, received blood transfusion or used blood products, or intend to&#xD;
             donate blood or blood components during or within 3 months after the test;&#xD;
&#xD;
         13. Nursing woman;&#xD;
&#xD;
         14. Subjects planned parenthood, unwillingness or inability to use effective&#xD;
             contraception, within 30 days before the trial (for women), and within six months&#xD;
             after the end of the trial;&#xD;
&#xD;
         15. Subjects who have taken any medicine (including Chinese herbal medicine) and health&#xD;
             care products within 14 days before the test;&#xD;
&#xD;
         16. Subjects who have taken any medicine that interacts with the drug or alters liver&#xD;
             enzyme activity within 30 days prior to the trial, such as cimetidine, haloperidol,&#xD;
             ketoconazole, clot-disrupting drugs (such as non-steroidal anti-inflammatory drugs,&#xD;
             aspirin and warfarin), Monoamine oxidase inhibitors (such as phenyledrine,&#xD;
             phenylamine, isazolid, isazolid, moclobemide, bromofaramine, nyalamide, tloxadone,&#xD;
             defloxadone, slegiline, linezolid, or methylene blue for intravenous use), similar to&#xD;
             other serotonin drugs (including triptans, selective serotonin reuptake inhibitors&#xD;
             (SSRIs), other serotonin and norepinephrine reuptake inhibitors (SNRIs), lithium,&#xD;
             sibutramine, tramadol or st John's wort, and tryptophan supplements) etc ;&#xD;
&#xD;
         17. Subjects who have eaten special diet (including grapefruit and/or food or drink rich&#xD;
             in xanthine derivatives or alcohol, such as tea and coffee, etc.) or have other&#xD;
             factors affecting drug absorption, distribution, metabolism and excretion within 14&#xD;
             days before the test;&#xD;
&#xD;
         18. Subjects who have special requirements on diet and cannot accept unified diet;&#xD;
&#xD;
         19. Subjects who have the difficulty in venous blood, or can not tolerate venipuncture, or&#xD;
             have a history of dizziness;&#xD;
&#xD;
         20. Subjects who need to drive and operate machines or engage in other potentially&#xD;
             dangerous activities during the test;&#xD;
&#xD;
         21. Other situations that the researchers considered unsuitable to enroll the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Wu, Dr</last_name>
    <phone>0086-10-58268486</phone>
    <email>trdrug@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institution of Drug Clinical Trials</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wu, Dr</last_name>
      <phone>0086-10-58268486</phone>
      <email>trdrug@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

